Literature DB >> 25636448

High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients.

Yongqing Xu1, Xianmin Bu, Chaoliu Dai, Chao Shang.   

Abstract

Previous studies have shown that some microRNAs (miRs) are intensively involved in the development of hepatocellular carcinoma. We analyzed the prognostic role of serum microRNA (miR-122) levels in hepatocellular carcinoma patients using a retrospective design. MiR-122 levels in 122 hepatocellular carcinoma patients were measured, and Cox regression analysis was performed to analyze the prognostic role of miR-122 in hepatocellular carcinoma, and the hazard ratio (HR) with 95 % confidence interval (95 %CI) was used to evaluate its prognostic role. Patients with large tumor size had lower levels of serum miR-122 (P = 0.04). However, there was no significant association of serum miR-122 levels with other clinical characteristics. Kaplan-Meier method showed that there was higher overall survival rate in hepatocellular carcinoma patients with high serum miR-122 levels compared with those with low miR-122 level (P < 0.01). When using Cox regression analysis, high serum miR-122 level was independently associated with better overall survival in hepatocellular carcinoma patients (HR = 0.26; 95 %CI 0.14-0.47, P < 0.01). Subgroup analysis by gender showed that high serum miR-122 level was independently associated with better overall survival in male patients (HR = 0.08; 95 %CI 0.03-0.22, P < 0.01), but not in female patients (HR = 0.48; 95 %CI 0.18-1.32, P = 0.16). Thus, the outcomes in the analysis suggest that high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636448     DOI: 10.1007/s13277-015-3128-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway.

Authors:  Jie Xu; Xiuming Zhu; Lingjiao Wu; Rong Yang; Zeran Yang; Qiangfeng Wang; Fusheng Wu
Journal:  Liver Int       Date:  2012-01-26       Impact factor: 5.828

Review 2.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 3.  Regulation of microRNA biogenesis.

Authors:  Minju Ha; V Narry Kim
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07-16       Impact factor: 94.444

Review 4.  The role of microRNAs in the control of innate immune response in cancer.

Authors:  Simon Jasinski-Bergner; Ofer Mandelboim; Barbara Seliger
Journal:  J Natl Cancer Inst       Date:  2014-09-12       Impact factor: 13.506

Review 5.  Regulation of microRNA function in somatic stem cell proliferation and differentiation.

Authors:  Archana Shenoy; Robert H Blelloch
Journal:  Nat Rev Mol Cell Biol       Date:  2014-08-13       Impact factor: 94.444

6.  Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion.

Authors:  Changfei Li; Yanzhong Wang; Saifeng Wang; Bo Wu; Junli Hao; Hongxia Fan; Ying Ju; Yuping Ding; Lizhao Chen; Xiaoyu Chu; Wenjun Liu; Xin Ye; Songdong Meng
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells.

Authors:  Patricia A Thibault; Adam Huys; Pearl Dhillon; Joyce A Wilson
Journal:  Virology       Date:  2012-12-13       Impact factor: 3.616

Review 8.  Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.

Authors:  André J Scheen; Luc F Van Gaal
Journal:  Lancet Diabetes Endocrinol       Date:  2014-02-19       Impact factor: 32.069

Review 9.  The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.

Authors:  Mark J Bolland; Andrew Grey; Greg D Gamble; Ian R Reid
Journal:  Lancet Diabetes Endocrinol       Date:  2014-01-24       Impact factor: 32.069

Review 10.  Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma.

Authors:  Priyanka Gupta; Murray J Cairns; Nitin K Saksena
Journal:  Virol J       Date:  2014-04-01       Impact factor: 4.099

View more
  16 in total

Review 1.  Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.

Authors:  Yu-Cheng Zhang; Zhuo Xu; Tian-Fu Zhang; Ya-Li Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

2.  Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.

Authors:  Norio Akuta; Yusuke Kawamura; Fumitaka Suzuki; Satoshi Saitoh; Yasuji Arase; Nozomu Muraishi; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Oncology       Date:  2021-11-17       Impact factor: 2.935

Review 3.  Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.

Authors:  Sijia Shen; Yuxin Lin; Xuye Yuan; Li Shen; Jiajia Chen; Luonan Chen; Lei Qin; Bairong Shen
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

4.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

Review 5.  Role of circulating microRNAs in liver diseases.

Authors:  Sven H Loosen; Florian Schueller; Christian Trautwein; Sanchari Roy; Christoph Roderburg
Journal:  World J Hepatol       Date:  2017-04-28

Review 6.  Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?

Authors:  Filippo Pelizzaro; Romilda Cardin; Barbara Penzo; Elisa Pinto; Alessandro Vitale; Umberto Cillo; Francesco Paolo Russo; Fabio Farinati
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 7.  Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.

Authors:  Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

Review 8.  Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Marta B Afonso; Pedro M Rodrigues; André L Simão; Rui E Castro
Journal:  J Clin Med       Date:  2016-03-03       Impact factor: 4.241

9.  Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.

Authors:  Yan Ding; Jia-Lai Yan; An-Ning Fang; Wei-Feng Zhou; Ling Huang
Journal:  Oncotarget       Date:  2017-07-04

Review 10.  Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Keiji Nishibeppu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.